JP Morgan Chase’s Satsuma Pharmaceuticals STSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-46,998
Closed -$195K – 7053
2022
Q2
$195K Buy
+46,998
New +$166K ﹤0.01% 5108
2021
Q3
– Sell
-21,707
Closed -$153K – 6960
2021
Q2
$153K Sell
21,707
-57,345
-73% -$309K ﹤0.01% 5379
2021
Q1
$467K Sell
79,052
-13,901
-15% -$84.2K ﹤0.01% 4735
2020
Q4
$429K Buy
92,953
+89,527
+2,613% +$386K ﹤0.01% 4480
2020
Q3
$13K Sell
3,426
-13,464
-80% -$271K ﹤0.01% 5247
2020
Q2
$486K Buy
16,890
+1,003
+6% +$23.2K ﹤0.01% 3879
2020
Q1
$341K Buy
15,887
+14,445
+1,002% +$328K ﹤0.01% 4046
2019
Q4
$28K Buy
+1,442
New +$20.5K ﹤0.01% 5298

Other funds holding STSA

JP Morgan Chase's STSA Position: Q3 2022 in Review

JP Morgan Chase sold out of Satsuma Pharmaceuticals (STSA) in Q3 2022, closing a stake of 46,998 shares — an estimated $195K sold.

JP Morgan Chase first reported a position in STSA in Q4 2019 and held it in 8 quarters. The position peaked at $486K in Q2 2020. 41 funds tracked by Wall St. Rank hold STSA as of Q3 2022.

  • JP Morgan Chase reported no remaining Satsuma Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • JP Morgan Chase sold 46,998 Satsuma Pharmaceuticals shares in Q3 2022, an estimated $195K.
  • JP Morgan Chase first reported a position in Satsuma Pharmaceuticals in Q4 2019 and held it in 8 quarters.
  • JP Morgan Chase's Satsuma Pharmaceuticals position peaked at $486K in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals as of Q3 2022.

Based on JP Morgan Chase's 13F filing for Q3 2022, filed 14 Nov 2022.